Advertisement

Topics

Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14

08:00 EST 7 Dec 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside chat at...

Other Sources for this Article

Aimmune Therapeutics Inc.
Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao, 650-351-6479
syao@aimmune.com

NEXT ARTICLE

More From BioPortfolio on "Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...